BioMarin Pharmaceutical | BMRN - Cost Of Sales

Stock Price
58.12
Daily Change
0.97 1.70%
Monthly
-5.20%
Yearly
-9.09%
Q1 Forecast
54.80

BioMarin Pharmaceutical reported $144.93M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Bayer EUR 4.31B 57M Sep/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Incyte USD 99M 20.23M Sep/2025
Insmed USD 30.9M 1.56M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
United Therapeutics USD 100.9M 74.3M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025